Xueba’s medical black technology system

Chapter 217 Goodbye Brennan, just in another form

Among the many cancer diseases, lung cancer is definitely second to none in terms of the number of patients.

But if we want to talk about the difficulty of cancer treatment, then pancreatic cancer is naturally the first to bear the brunt.

Pancreatic cancer has a high degree of progression and is not sensitive to radiotherapy or chemotherapy.

For example, lung cancer or gastric cancer can be treated with surgical resection if you are lucky.

The location of pancreatic cancer is hidden and there are relatively many blood vessels and important organs around it.

Even if it is detected early, surgery is very difficult, which is why some patients die from complications without surgery.

Among all solid malignant tumors, the incidence and mortality rate of pancreatic cancer is closest to 1:1!

Therefore, this also gives pancreatic cancer another name, the king of cancer!

According to the reward prompts given by the system.

Peptidyl prolyl isomerase Pin1 is the target of pancreatic cancer, the “king of cancers”!
This somewhat surprised Lu Liang. He did not expect that Pin1, an isomerase that has basically nothing to do with cancer, would one day become a target for pancreatic cancer.

If this were told, it would probably surprise many people.

Lu Liang continued to write the test plan, even though the target was given by the system.

But he still needs a batch of experimental results to determine exactly how Pin1 plays a role in cancer.

Lu Liang's idea is also very simple. Take a group of mice with Pin1 knocked out and normal mice as controls.

Then see which cells in the body of Pin1-deficient mice and normal mice are regulated under the same environmental conditions.

I need to find time to do this experiment briefly.

Thinking of this, Lu Liang looked at Wang Wentao on the side.

At this moment, Wang Wentao was finishing up the last piece of fried chicken, then picked up the Coke next to him and took a big sip.

Lu Liang smiled and asked, "Are you full?"

Wang Wentao patted his bulging belly, then burped with satisfaction and said, "I'm full."

Lu Liang grinned and said, "Now that I'm full, shouldn't I do something to digest it?"

Hearing Lu Liang's words, Wang Wentao was stunned for a moment, and then reacted: "Is there any work to do again?"

Lu Liang's experiment was not designed to be too difficult.

There is no need for any cumbersome drug administration or injection, just feed a little feed every day and keep it as if it were a pet.

Anyway, Wang Wentao goes to the rat room every day to do some animal experiments, and he did this experiment together.

While Lu Liang was thinking about these things, a shout rang at the door of the study room.

Lu Liang looked back and found Ji Hong standing at the door of the study room.

"Teacher, what's the matter?" Lu Liang asked.

"Xiao Lu, come with me, I have something to ask you." Ji Hong waved to Lu Liang and said.

This surprised Lu Liang a little.

Lu Liang didn't think much about it. After he followed Ji Hong out of the study room, the two of them came to the office.

Ji Hong sat down at his desk, then smiled and asked, "Are you busy during this time?"

Ji Hong has been on a business trip during this period. He just came back from his business trip two days ago, so he naturally doesn't know much about what happened in the school during this period.

Lu Liang replied: "I did something with Wang Wentao about the generic clobazam drug before, but there is nothing else."

Ji Hong nodded: "I've also heard that, this matter is indeed done well."

Lu Liang asked: "By the way, teacher, why are you looking for me?"

It was impossible for Ji Hong to find him just to briefly understand his work during this period. For this kind of thing, he could just ask Wang Wentao.Ji Hong smiled and said, "I called you here because I wanted to show you something."

With that said, Ji Hong opened his computer.

Lu Liang also came up curiously at this time, wanting to see what Ji Hong was talking about.

Soon, Ji Hong opened his computer mailbox. There was a document attachment in the mailbox. When the attachment was opened, it was a paper.

The title of the paper is: "Prognosis and Physiological Function of MiR-3159 in Non-Small Cell Lung Cancer".

Ji Hong explained: "This is a paper that has not been published yet, and I am currently reviewing it."

Lu Liang nodded suddenly. Ji Hong occasionally received requests from editors of various journals to help review articles in related professional fields.

This is a very normal thing.

After all, there are specialties in the academic field, and it is impossible for editors to know enough about the research in each professional field. They can only conduct a rough screening of submitted articles.

As for the quality of the article, it can only be reviewed by scientific researchers in relevant research fields.

And most scientific researchers will not refuse requests in this regard.

Ji Hong looked at Lu Liang and asked, "What do you think of this article?"

Although he didn't quite understand why Ji Hong wanted to ask for his opinion, Lu Liang still briefly glanced at the paper.

The work of this paper cannot be said to be that special and innovative.

Perhaps the only innovative point is to conduct supplementary research on the non-coding RNA that has regulatory functions, such as miR, which fills the gap in this part of the research.

Lu Liang thought for a moment and replied: "Just so so."

Lu Liang gave his own evaluation.

Ji Hong continued: "This article is now submitted to Science Translational Medicine."

Science Translational Medicine?

When Lu Liang heard about this journal, he was stunned for a moment.

This is a sub-journal of Science, which mainly includes reports and discussions on basic scientific research, translational medical research, and clinical research on human diseases.

This year’s impact factor has reached 17.

In medical-related fields, it is considered half of the top journals.

"Teacher, then you can just give me the rejection opinion." Lu Liang said simply.

It's not that Lu Liang belittles the standard of this article, it's that the standard of this article is really not high.

After reading the abstract of this paper, Lu Liang had roughly guessed what the paper was about.

A paper of this level is probably at the level of a Section [-] Sci. Being published in a Section [-] Sci is already incredible. How can it be published in a Science sub-journal?

Ji Hong continued: "But the other two reviewers gave their opinions in agreement."

"Huh? Are those two reviewers blind?" Lu Liang almost blurted out.

Ji Hong smiled: "Look who signed this paper?"

When Ji Hong said this, Lu Liang looked at the signature of the article in confusion. Neither the first author nor the second author of the article had much problem.

Then, Lu Liang looked at the corresponding author of the article.

However, when Lu Liang saw the name of the corresponding author, he was stunned for a moment.

It can be said that Lu Liang is very familiar with the name as the corresponding author of this paper.

Murray Brennan!
(End of this chapter)